324 related articles for article (PubMed ID: 25027606)
1. Novel treatments with small molecules in psoriatic arthritis.
Hansen RB; Kavanaugh A
Curr Rheumatol Rep; 2014; 16(9):443. PubMed ID: 25027606
[TBL] [Abstract][Full Text] [Related]
2. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
[TBL] [Abstract][Full Text] [Related]
3. Small molecule therapy for managing moderate to severe psoriatic arthritis.
Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
[TBL] [Abstract][Full Text] [Related]
4. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
5. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
6. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
7. New targets in psoriatic arthritis.
Braun J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
[TBL] [Abstract][Full Text] [Related]
8. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
9. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
11. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
12. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
[TBL] [Abstract][Full Text] [Related]
13. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
14. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
15. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
16. Apremilast for the treatment of psoriatic arthritis.
Martin BC; Thomas LW; Dann FJ
Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329487
[TBL] [Abstract][Full Text] [Related]
17. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
18. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
20. Apremilast in psoriatic arthritis.
Schett G
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
